SCHEMBL5734845

SCHEMBL5734845

CCOP(=O)(O)CC(=O)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.57
LMNA P02545 1/20 0.57
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
NPC1 O15118 2/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 3/20 0.44
MAPT P10636 3/20 0.44
KDM4E B2RXH2 1/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
CES1 P23141 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
CETP P11597 3/20 0.43
NR1I2 O75469 1/20 0.42
KCNH2 Q12809 1/20 0.42
GSK3B P49841 2/20 0.41
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28005057 0.98 POLB (0.56) POLBLMNAMEN1KMT2ANPC1
SCHEMBL5734397 0.88 ERCC5 (0.50) POLBLMNANPC1SMN1; SMN2HPGD
SCHEMBL5734479 0.87 L3MBTL1 (0.50) POLBLMNAMEN1KMT2AMAPK1
SCHEMBL5734543 0.84 LMNA (0.42) POLBLMNASMN1; SMN2CETPPTPN1
SCHEMBL5733094 0.84 ERCC5 (0.53) POLBLMNAMEN1KMT2ANPC1
SCHEMBL1305579 0.84 POLB (0.59) POLBLMNAMEN1KMT2ANPC1
SCHEMBL28002451 0.83 TSHR (0.56) POLBLMNAKMT2ANPC1SMN1; SMN2
SCHEMBL2322449 0.83 HTR7 (0.47) POLBLMNAMEN1KMT2ANPC1
SCHEMBL5733074 0.83 L3MBTL1 (0.47) POLBLMNAMEN1KMT2ANPC1
SCHEMBL5732716 0.83 KDM4E (0.45) POLBLMNAMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 POLB 3426/4885LMNA 3569/4885MEN1 4630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.